Lymphocyte antigen 6 complex, locus K (LY6K)

Lymphocyte antigen 6 complex, locus K (LY6K) is a glycosylphosphatidylinositol (GPI)-anchored cell surface protein belonging to the Ly6/uPAR superfamily [1, 10]. It is primarily recognized as a cancer-testis antigen, meaning its physiological expression is largely restricted to the testis, but it is aberrantly overexpressed in a wide range of malignancies, including lung, esophageal, breast, and bladder cancers [1, 2, 12]. In the context of oncology, LY6K acts as an oncogene by promoting cell proliferation, migration, and invasion, often through the activation of the ERK/MAPK signaling pathway and the modulation of TGF-beta signaling [1, 12, 15]. Its highly tumor-specific expression profile makes it an attractive target for precision immunotherapy, including the development of peptide vaccines and antibody-based therapeutics [1, 6, 14]. Clinical trials have investigated LY6K-derived peptide vaccines, such as LY6K-177, which aim to stimulate a cytotoxic T-lymphocyte response against tumor cells while sparing normal tissues [1, 6, 18]. Additionally, LY6K has shown promise as a diagnostic and prognostic biomarker, with elevated serum levels correlating with advanced disease stages and poor patient survival [1, 2]. Preclinical studies have also explored small molecule inhibitors like NSC243928 to disrupt LY6K-mediated signaling and induce cancer cell death [12, 14]. While targeting LY6K is generally well-tolerated, potential safety considerations include its role in male fertility, as it is required for sperm migration in the reproductive tract [4, 12].

Other names

LY6KCancer/testis antigen 97CT97HSJ001348CO16Up-regulated in lung cancer 10URLC10FLJ35226Lymphocyte antigen 6 family member K

Peptide vaccine induction of cytotoxic T-lymphocyte response, small molecule inhibition of signaling, and gene silencing via siRNA/shRNA.